Daniel Janney

Daniel Janney has an estimated net worth of $819 Million. This is based on reported shares across multiple companies, which include IMMUNE DESIGN CORP., ZS Pharma, Inc., SUTRO BIOPHARMA, INC., TREVENA INC, APPLIED GENETIC TECHNOLOGIES CORP, aTYR PHARMA INC, Neothetics, Inc., ANESIVA, INC., ATS MEDICAL INC, RENOVIS INC, Allakos Inc., OCCAM NETWORKS INC/DE, COTHERIX INC, CUTERA INC, DYNAVAX TECHNOLOGIES CORP, NeurogesX Inc, Krystal Biotech, Inc., Tyra Biosciences, Inc., Carbylan Therapeutics, Inc., Esperion Therapeutics, Inc., AERIE PHARMACEUTICALS INC, VIVEVE MEDICAL, INC., ACELRX PHARMACEUTICALS INC, ICAGEN INC, FLAMEL TECHNOLOGIES SA, ELLIE MAE INC, TorreyPines Therapeutics, Inc., and INTARCIA THERAPEUTICS, INC.

2014 was Daniel Janney's most active year for acquiring shares with 27 total transactions. Daniel Janney's most active month to acquire stocks was the month of January. 2014 was Daniel Janney's most active year for disposing of shares, totalling 27 transactions. Daniel Janney's most active month to dispose stocks was the month of January. 2014 saw Daniel Janney paying a total of $28,496,905.70 for 16,804,389 shares, this is the most they've acquired in one year. In 2003 Daniel Janney cashed out on 3,325,000 shares for a total of $63,177,849.99, their largest year based on trade value.